EGFR靶向药物治疗非小细胞肺癌的研究进展

在世界范围内,肺癌是死亡率最高的恶性肿瘤,其中以非小细胞肺癌(non-small cell lung cancer,NSCLC)为主.近年来,随着人表皮生长因子受体(epidermal growth factor receptor,EGFR)突变体的发现,以吉非替尼(gefitinib)和厄洛替尼(erlotinib)为代表的EGFR酪氨酸激酶抑制剂(EGFR-TKIs)对于携带有EGFR敏感突变的NSCLC具有良好的疗效.然而,耐药问题的出现增加了临床治疗的难度,针对非小细胞肺癌的EGFR靶向治疗,目前仍有很多问题亟待解决.本文现就EGFR靶向治疗的现状与发展进行综述.

Progress of EGFR-targeted therapy for NSCLC

Lung cancer is the leading cause of cancer-related death worldwide, and among them non-small cell lung cancer (NSCLC) accounts for a high proportion.With the presence of human epidermal growth factor receptor(EGFR), EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have a good therapeutic effect on NSCLC patients with sensitive EGFR-mutant.However,the presence of drug resistance increases the difficulty of EGFR-targeted therapy in clinic and there are still many problems to be solved.This review aims to summarize the current knowledge and future prospects of the use of EGFR targeted therapies to treat NSCLC.